The dosage regimen of levamisole in cancer: is it related to efficacy and safety?
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D000380:Agranulocytosis / Q000139:chemically induced / Q000150:complications; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005387:Finland; D006258:Head and Neck Neoplasms / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007978:Levamisole / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy; D008297:Male; D051379:Mice
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D007978:Levamisole